Encephalopathies: Zerlyn T. Leonardo, M.D., FPCP, FPNA
Encephalopathies: Zerlyn T. Leonardo, M.D., FPCP, FPNA
Encephalopathies: Zerlyn T. Leonardo, M.D., FPCP, FPNA
Reversible --------------------------------Irreversible
Reversible --------------------------------Irreversible
Amnestic state,
Dementia
HIE: Pathology
HIE secondary to hypoxia
• Brain cells most vulnerable to hypoxia
1. Hippocampal pyramidal cells of CA1
2. Layers 3 and 5 of the Neocortex
3. Purkinje cells
4. Striatal neurons (basal ganglia)
HIE: Pathology
• Laminar Necrosis
• Laminar Necrosis
HIE: Pathology
HIE secondary to hypoxia
• Brain cells most vulnerable to hypoxia
1. Hippocampal pyramidal cells of CA1
2. Layers 3 and 5 of the Neocortex
3. Purkinje cells
4. Striatal neurons (basal ganglia)
HIE: Pathology
• Purkinje cell death
Cerebellar Ataxia
Motor Incoordination
HIE: Pathology
HIE secondary to hypoxia
• Brain cells most vulnerable to hypoxia
1. Hippocampal pyramidal cells of CA1
2. Layers 3 and 5 of the Neocortex
3. Purkinje cells
4. Striatal neurons (basal ganglia)
HIE: Pathology
• Striatal Neuronal
death
Parkinsonism
Choreoathetosis
HIE: Pathology
• HIE secondary to hypotension
Result in Watershed Infarction
HIE: Pathology
• HIE secondary to
hypotension
Result in Watershed
Infarction
Visual Agnosia,
“Man-in-a-barrel” weakness
HIE: Diagnosis
• Hx of hypoxic-ischemic event
Cardiac Arrest
Blood pressure < 70 mmHg systolic or
PaO2 < 40 mmHg, and the duration
• Elevated CarboxyHb level + Cherry Red
skin color
Carbon monoxide intoxication hypoxia
HIE: Treatment
• Restore normal cardiorespiratory
function
• Hypothermia to target Temp of 32-34°C
for 12-24 hours
• Hyperbaric Oxygen for CO intoxication
• Anticonvulsants for myoclonic seizures
Clonazepam 1.5-10 mg daily
Valproate 300-1200 mg daily
HIE: Prognosis
• Uncommon phenomenon
Patients with CO and Cyanide intoxication
• No evident clinical impairment initially
• Develop parkinsonian features (akinesia and
rigidity but without tremors)
Patients initially recovering from a hypoxic-
ischemic event develop a relapse
• Apathy, confusion, agitation
Delayed Post-anoxic Encephalopathy
• Progressive neurologic deficits
shuffling gait, diffuse rigidity and spasticity
persistent parkinsonism or myoclonus
• Occasionally coma and death after 1–2
weeks
• Pathology:
Widespread cerebral demyelination may be
present
Damage to the basal ganglia
Delayed Post-anoxic Encephalopathy
Metabolic Encephalopathy
Metabolic Encephalopathy
• Disorders of cerebral function due to:
Vital organ failure (liver, kidney)
Electrolyte imbalances (sodium)
Hypoglycemia
Hyperglycemia
Endocrine disorders (Thyroid storm,
Myxedema, SIADH, Hashimoto, DI)
Metabolic Encephalopathy:
Clinical Manifestation
• Varies:
Mild confusional state deep coma with
decerebrate posturing
• Delirium or acute confusional state
usually the earliest recognized brain malfunction
Patients may be:
• agitated, usually with increased sympathetic nervous
system activity, or
• quiet and withdrawn
Metabolic Encephalopathy:
Diagnosis
• Clues:
Background of vital organ dysfunction or
history of some event, e.g. toxic exposure
that would upset the metabolic milieu of the
brain
Time course of symptoms:
• Acute or recent in onset
• Fluctuating level of consciousness
• Coherent and obeying at one point, and a few hours
later in a stupor
Metabolic Encephalopathy:
Diagnosis
• Clues:
PE: Jaundice, hyperventilation, tremors,
asterixis, multifocal myoclonus
Neuro exam:
• Cranial nerve reflexes generally spared except
in Wernicke’s encephalopathy (affects
vestibuloocular reflex)
Metabolic Encephalopathy:
Treatment
• Treat the underlying problem
• Low dose neuroleptics for severe
agitation
Septic Encephalopathy
Septic Encephalopathy:
Pathophysiology
Sepsis
Multiorgan
Failure Septic Encephalopathy
Septic Encephalopathy: Diagnosis